Casandra
Casandra Test Code QD74283Version 1 (DRAFT)
Performing Lab
CEA with HAMA Treatment
Clinical Use
Order TestUse
CEA is a tumor marker that is useful to monitor patients with persistent, recurrent or metastatic colonic carcinoma. Patients who have received mouse monoclonal antibodies as part of treatment should have their specimens pre‑treated for removal of the human antimouse antibodies (HAMA).
Special Instructions
Not provided.
Limitations
Approximately 5% of colorectal cancers are not associated with increased levels of CEA. CEA may be elevated in many types of solid cancer.
Test Details
Methodology
Immunoassay (Other)
Biomarkers
CEA
AnalyteCEA • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
CEA, Untreated
AnalyteCEA Untreated • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
HAMA Treated
ProteinHAMA Treated CEA • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Transport tube
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 28 days |
Related Tests
Other tests from different labs that may be relevant
Carcinoembryonic Antigen (CEA) (Serial Monitor)
Labcorp
Carcinoembryonic Antigen (CEA)
Labcorp
Carcinoembryonic Antigen (CEA), Serum
Mayo Clinic Lab
Carcinoembryonic Antigen
ARUP Laboratories
Cancer Antigen (CA) 125 in the Presence of Human Antimouse Antibodies (HAMA)
Labcorp
Human Antimouse Antibodies
Labcorp
Human Anti-mouse Antibody (HAMA)
Mayo Clinic Lab
Carbohydrate Antigen (CA) 19-9 (Serial Monitor)
Labcorp
Breast Carcinoma-Associated Antigen, Serum
Mayo Clinic Lab